• 1
    Perilongo G, Shafford E, Plaschkes J. Liver Tumour Study Group of the International Society of Paediatric Oncology. SIOPEL trials using preoperative chemotherapy in hepatoblastoma [review]. Lancet Oncol. 2000; 1: 94-100.
  • 2
    Stiller CA, Pritchard J, Steliarova-Foucher E. Liver cancer in European children: incidence and survival,1978-1997. Report from the Automated Childhood Cancer Information System Project. Eur J Cancer. 2006; 42: 2115-2123.
  • 3
    Evans AE, Land VJ, Newton WA, et al. Combination chemotherapy (vincristine, Adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoma. Cancer. 1982; 50: 821-826.
  • 4
    Ortega JA, Krailo MD, Haas JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group. J Clin Oncol. 1991; 9: 2167-2176.
  • 5
    Douglass EC, Reynolds M, Finegold M, et al. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1993; 11: 96-99.
  • 6
    Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000; 18: 2665-2675.
  • 7
    von Schweinitz D, Byrd DJ, Hecker H, et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer. 1997; 33: 1243-1249.
  • 8
    Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology—SIOPEL 2. Eur J Cancer. 2004; 40: 411-421.
  • 9
    Knight KRG, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005; 23: 8588-8596.
  • 10
    Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose [see comment]. Eur J Cancer. 2004; 40: 2445-2451.
  • 11
    Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J Clin Oncol. 2007; 25: 708-714.
  • 12
    Katzenstein HM, Chang KW, Krailo M, et al. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. Cancer. 2010; 116: 5829-5836.
  • 13
    Rybak LP, Whitworth CA. Ototoxicity: therapeutic opportunities. Drug Discov Today. 2005; 10: 1313-1321.
  • 14
    Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hearing Res. 2007; 226: 157-167.
  • 15
    Fulda S, Fichtner I, Hero B, Berthold F. Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients. Med Pediatr Oncol. 2001; 36: 199-202.
  • 16
    Petrilli AS, Oliveira DT, Ginani VC, et al. Use of amifostine in the therapy of osteosarcoma in children and adolescents. J Pediatr Hematol Oncol. 2002; 24: 188-191.
  • 17
    Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer. 2005; 104: 841-847.
  • 18
    Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma [see comment]. J Clin Oncol. 2008; 26: 3749-3755.
  • 19
    Neuwelt EA, Gilmer-Knight K, Lacy C, et al. Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption [see comment]. Pediatr Blood Cancer. 2006; 47: 174-182.
  • 20
    Rybak LP. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolar Head Neck Surg. 2007; 15: 364-369.
  • 21
    Freyer DR, Sung L, Reaman GH. Prevention of hearing loss in children receiving cisplatin chemotherapy [comment]. J Clin Oncol. 2009; 27: 317-318; author reply 318-319.